ABT-957

DRUG2 trials

Sponsors

AbbVie

Conditions

Alzheimer's DiseaseMild Cognitive Impairment

Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

TerminatedNCT02220738

AbbVieAlzheimer's Disease

Start: 2014-09-30End: 2016-03-31Updated: 2021-07-06

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

TerminatedNCT02573740

AbbVieAlzheimer's Disease, Mild Cognitive Impairment

Start: 2015-12-31End: 2016-06-30Updated: 2021-07-06